Core Insights - SINTX Technologies has published a peer-reviewed study demonstrating the antiviral efficacy of silicon nitride against various virus strains, including SARS-CoV-2 and MERS-CoV [1][2][4] Company Overview - SINTX Technologies is an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄) and is the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S. [3][5][10] - The company is transitioning from a single-product orthopedic implant manufacturer to a platform technology company with broad applications in infection control and medical devices [9] Study Findings - The study showed that alpha-phase silicon nitride (α-Si₃N₄) can reduce infectious SARS-CoV-2 titers by up to 99.97% within 10 minutes, with complete inactivation observed by 30 minutes [4] - When embedded in textile fabric, silicon nitride achieved 97% inactivation, demonstrating broad-spectrum virucidal activity against several SARS-CoV-2 variants and MERS-CoV [4] Market Opportunity - The global infection-prevention and control market is projected to exceed $230 billion by 2032, with the antiviral PPE market estimated to reach over $40 billion by 2030 and the global wound care market forecast to surpass $30 billion by 2030 [6] - SINTX believes its silicon nitride-based products can capture significant market share in these sectors due to their superior safety profile and performance compared to traditional metal-based antimicrobials [6] Advantages of Silicon Nitride - Unlike traditional antimicrobial additives like copper and silver, silicon nitride releases non-toxic reactive nitrogen species that damage viral RNA and proteins without harming surrounding tissue [7] - Potential applications include wound dressings, surgical sutures, face masks, hospital linens, and HEPA filters [8] Strategic Positioning - The publication of the study marks a strategic milestone for SINTX as it seeks partnerships and licensing opportunities to accelerate commercialization of its technology [9]

Core Insights - Sintx Technologies, Inc. announced the retirement of Dr. Sonny Bal as Chairman of the Board, with Eric Olson, the current CEO, appointed as the new Chairman effective immediately [1][2] Leadership Transition - Dr. Bal has been Chairman since 2015 and has significantly contributed to Sintx's transformation and growth in advanced materials [2] - Eric Olson expressed gratitude for Dr. Bal's leadership and emphasized the company's focus on high-value medical applications and strategic partnerships moving forward [3] - Since becoming CEO in August 2024, Olson has redirected the company towards high-growth opportunities in biomedical and medical device sectors [3] Company Overview - Sintx Technologies specializes in advanced ceramics for medical applications and is a leader in the research and manufacturing of silicon nitride, with products implanted in humans since 2008 [4] - The company has pursued strategic acquisitions and alliances to expand into new markets [4]